Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Takeda Pharmaceutical said on June 17 that its investigational treatment soticlestat, also known as TAK-935, could not reach the primary goals in two PIII clinical studies targeting rare forms of epilepsies. The trials respectively covered Dravet syndrome and Lennox-Gastaut syndrome,…
To read the full story
Related Article
- Takeda Drops Epilepsy Med Soticlestat after PIII Miss
January 31, 2025
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





